Increlex® resources for Healthcare Professionals

Increlex® (mecasermin) is indicated for the treatment of growth failure in children
and adolescents from 2–18 years with confirmed severe primary insulin-like
growth factor-1 deficiency defined by:

  • Height SD score ≤ –3.0
  • Basal IGF-1 levels < 2.5th percentile for age and gender
  • GH sufficiency
  • Exclusion of secondary forms of IGF-1 deficiency, such as malnutrition,
    hypopituitarism, hypothyroidism, or chronic treatment with pharmacologic
    doses of anti-inflammatory steroids

Severe primary IGF-1 deficiency can include patients with mutations in the GH receptor (GHR) gene/Laron’s syndrome, post-GHR signaling pathway, and IGF-1 gene defects; they are not GH-deficient and therefore cannot be expected to respond adequately to exogenous GH treatment.

Increlex® is not recommended in children <2 years of age.

Consult the Product Monograph at health-products.canada.ca/dpd-bdpp/ for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use. The Product Monograph is also available by calling Ipsen Medical Information at 1-855-215-2288.

Increlex® – Product Overview

Dosage and Administration Guide

Patient Identification Checklist

Product Monograph

IPSEN CARES® (Coverage, Access, Reimbursement & Education Support) is a comprehensive support program that serves as a central point of contact
among patients, caregivers, doctors’ offices, insurance companies, and specialty pharmacies.

Our priority is to offer services to support your patients throughout their individual treatment journey. For more information about the program, call 1-855-215-2288 Monday to Friday.

The IPSEN CARES® patient support program is here to support your patients on their Increlex® treatment journey by offering the following suite of services:

Registered Nurse case managers

  • Provide continuous support and repeated injection training (if requested)
  • Investigate financial assistance options
  • Submit applications for drug coverage

At-home medication delivery

  • Optional home delivery of medication
  • In-depth product counselling by a certified pharmacist if dispensed through the program

At-home injection training

  • At-home injection training with your patient and their caregivers, including a mock injection
  • Pre-treatment height measurement

IPSEN CARES® welcome kit

  • Includes materials to support your patient’s treatment journey

Call centre service

  • Offers ongoing support for your patient and their healthcare provider team
  • All inquiries will be responded to within 1 business day

Contact us at 1-855-215-2288

IPSEN CARES® Brochure

How can patients enrol in IPSEN CARES®?

Fill out an enrolment form for your patient and fax it to IPSEN CARES®.

Your patient will receive a call from IPSEN CARES® confirming their enrolment in the program and offering additional information on the support they will receive throughout their treatment journey.

Patients will have ongoing access to the services outlined above.

For more information about the program,
call 1-855-215-2288 Monday to Friday

The IPSEN CARES® program is available only for products that are authorized for sale by Health Canada.
REFERENCES: INCRELEX Product Monograph. Ipsen Biopharmaceuticals Canada Inc.